{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T23:15:44Z","timestamp":1791674144961,"version":"4.3.4"},"reference-count":130,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","schres-journal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.schres.2016.11.027","type":"journal-article","created":{"date-parts":[[2016,11,29]],"date-time":"2016-11-29T19:52:40Z","timestamp":1480449160000},"page":"2-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"special_numbering":"C","title":["Intranasal delivery of antipsychotic drugs"],"prefix":"10.1016","volume":"184","author":[{"given":"Yogesh K.","family":"Katare","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin E.","family":"Piazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7948-7592","authenticated-orcid":false,"given":"Jayant","family":"Bhandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritesh P.","family":"Daya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosalan","family":"Akilan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline J.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Hoare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram K.","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2016.11.027_bb0005","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ijpharm.2013.04.084","article-title":"Brain targeting of olanzapine via intranasal delivery of core-shell difunctional block copolymer mixed nanomicellar carriers: in vitro characterization, ex vivo estimation of nasal toxicity and in vivo biodistribution studies","volume":"452","author":"Abdelbary","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.schres.2016.11.027_bb0010","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ijpharm.2015.05.064","article-title":"Investigating the cubosomal ability for transnasal brain targeting: in vitro optimization, ex vivo permeation and in vivo biodistribution","volume":"490","author":"Abdelrahman","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.schres.2016.11.027_bb0015","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1602\/neurorx.2.4.554","article-title":"Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery","volume":"2","author":"Alavijeh","year":"2005","journal-title":"NeuroRx"},{"key":"10.1016\/j.schres.2016.11.027_bb0020","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2337\/diacare.27.2.596","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"27","author":"American Diabetic Association","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.schres.2016.11.027_bb0025","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/0306-4522(91)90354-Q","article-title":"Central projections of trigeminal primary afferents innervating the nasal mucosa: a horseradish peroxidase study in the rat","volume":"41","author":"Anton","year":"1991","journal-title":"Neuroscience"},{"key":"10.1016\/j.schres.2016.11.027_bb0030","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/1099-081X(199911)20:8<369::AID-BDD200>3.0.CO;2-6","article-title":"Pharmacokinetics and tissue distribution of olanzapine in rats","volume":"20","author":"Aravagiri","year":"1999","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.schres.2016.11.027_bb0035","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1359-6446(02)02452-2","article-title":"Permeability issues in nasal drug delivery","volume":"7","author":"Arora","year":"2002","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.schres.2016.11.027_bb0040","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2478\/v10007-008-0014-3","article-title":"A study of rivastigmine liposomes for delivery into the brain through intranasal route","volume":"58","author":"Arumugam","year":"2008","journal-title":"Acta Pharma."},{"key":"10.1016\/j.schres.2016.11.027_bb0045","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/BF00237470","article-title":"Transneuronal transport of peroxidase-conjugated wheat germ agglutinin (WGA-HRP) from the olfactory epithelium to the brain of the adult rat","volume":"63","author":"Baker","year":"1986","journal-title":"Exp. Brain Res."},{"key":"10.1016\/j.schres.2016.11.027_bb0050","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/cne.902510209","article-title":"Avenues for entry of peripherally administered protein to the central nervous system in mouse, rat, and squirrel monkey","volume":"251","author":"Balin","year":"1986","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.schres.2016.11.027_bb0055","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1208\/s12249-014-0189-5","article-title":"Intranasal drug delivery of olanzapine-loaded chitosan nanoparticles","volume":"15","author":"Baltzley","year":"2014","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.schres.2016.11.027_bb0060","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1124\/jpet.103.063222","article-title":"Brain uptake of the glucagon-like peptide-1 antagonist exendin(9-39) after intranasal administration","volume":"309","author":"Banks","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.schres.2016.11.027_bb0065","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.pbb.2008.09.003","article-title":"Subchronic MK-801 behavioural deficits in rats: partial reversal by the novel nitrate GT 1061","volume":"91","author":"Beninger","year":"2009","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.schres.2016.11.027_bb0070","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.schres.2014.03.035","article-title":"Glial cells as key players in schizophrenia pathology: recent insights and concepts of therapy","volume":"161","author":"Bernstein","year":"2015","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2016.11.027_bb0075","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1023\/A:1007594602449","article-title":"Biovector nanoparticles improve antinociceptive efficacy of nasal morphine","volume":"17","author":"Betbeder","year":"2000","journal-title":"Pharm. Res."},{"key":"10.1016\/j.schres.2016.11.027_bb0080","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.addr.2011.11.014","article-title":"Nanomaterial-mediated CNS delivery of diagnostic and therapeutic agents","volume":"64","author":"Biddlestone-Thorpe","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.schres.2016.11.027_bb0085","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000321044","article-title":"Nasal drug delivery in humans","volume":"40","author":"Bitter","year":"2011","journal-title":"Curr. Probl. Dermatol."},{"key":"10.1016\/j.schres.2016.11.027_bb0090","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nn0602-849","article-title":"Sniffing neuropeptides: a transnasal approach to the human brain","volume":"5","author":"Born","year":"2002","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.schres.2016.11.027_bb0095","first-page":"F329","article-title":"Drainage of cerebral interstitial fluid into deep cervical lymph of the rabbit","volume":"240","author":"Bradbury","year":"1981","journal-title":"Am. J. Phys."},{"key":"10.1016\/j.schres.2016.11.027_bb9000","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.euroneuro.2016.08.001","article-title":"Oxytocin to modulate emotional processing in schizophrenia: A randomized, double-blind, cross-over clinical trial","volume":"26","author":"Brambilla","year":"2016","journal-title":"Eur Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2016.11.027_bb0100","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3109\/10611860108997935","article-title":"Transport of nanoparticles across the rat nasal mucosa","volume":"9","author":"Brooking","year":"2001","journal-title":"J. Drug Target."},{"key":"10.1016\/j.schres.2016.11.027_bb0105","article-title":"Unaltered oxytocin and vasopressin plasma levels in patients with schizophrenia after a 4-month daily treatment with intranasal oxytocin","volume":"28","author":"Busnelli","year":"2015","journal-title":"J. Neuroendocrinol."},{"key":"10.1016\/j.schres.2016.11.027_bb0110","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jconrel.2014.05.003","article-title":"Chitosan in nasal delivery systems for therapeutic drugs","volume":"190","author":"Casettari","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.schres.2016.11.027_bb0115","first-page":"1322","article-title":"Advantageous nasal drug delivery system: a review","volume":"2","author":"Chhajed","year":"2011","journal-title":"Int. J. Pharm. Sci. Rev. Res."},{"key":"10.1016\/j.schres.2016.11.027_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2007.03.025","article-title":"Intranasal delivery: physicochemical and therapeutic aspects","volume":"337","author":"Costantino","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.schres.2016.11.027_bb0125","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/j.1755-5949.2010.00199.x","article-title":"Nanoparticulate systems for drug delivery and targeting to the central nervous system","volume":"17","author":"Craparo","year":"2011","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.schres.2016.11.027_bb0130","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.schres.2016.02.011","article-title":"Do we need oxytocin to treat schizophrenia? A randomized clinical trial","volume":"172","author":"Dagani","year":"2016","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2016.11.027_bb0140","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0033-3182(10)70664-2","article-title":"The pharmacokinetics of paliperidone versus risperidone","volume":"51","author":"de Leon","year":"2010","journal-title":"Psychosomatics"},{"key":"10.1016\/j.schres.2016.11.027_bb0145","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1002\/jps.21924","article-title":"Intranasal delivery to the central nervous system: mechanisms and experimental considerations","volume":"99","author":"Dhuria","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.schres.2016.11.027_bb0150","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1089\/jamp.2011.0924","article-title":"Nasal deposition and clearance in man: comparison of a bidirectional powder device and a traditional liquid spray pump","volume":"25","author":"Djupesland","year":"2012","journal-title":"J. Aerosol. Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.schres.2016.11.027_bb0155","author":"DRUGBANK Drug and Target Database"},{"key":"10.1016\/j.schres.2016.11.027_bb0160","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.schres.2012.05.018","article-title":"Adjunctive intranasal oxytocin improves verbal memory in people with schizophrenia","volume":"139","author":"Feifel","year":"2012","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2016.11.027_bb0165","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.biopsych.2010.04.039","article-title":"Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients","volume":"68","author":"Feifel","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2016.11.027_bb0170","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1166\/jbn.2015.2078","article-title":"Mucoadhesive amphiphilic methacrylic copolymer-functionalized poly(epsilon-caprolactone) nanocapsules for nose-to-brain delivery of olanzapine","volume":"11","author":"Fonseca","year":"2015","journal-title":"J. Biomed. Nanotechnol."},{"issue":"Suppl. 3","key":"10.1016\/j.schres.2016.11.027_bb0175","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/S0924-977X(03)00096-8","article-title":"Benefits of different drug formulations in psychopharmacology","volume":"13","author":"Frijlink","year":"2003","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2016.11.027_bb0180","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.schres.2014.04.009","article-title":"A pilot six-week randomized controlled trial of oxytocin on social cognition and social skills in schizophrenia","volume":"156","author":"Gibson","year":"2014","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2016.11.027_bb0185","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.peptides.2010.10.030","article-title":"Microtubules, schizophrenia and cognitive behavior: preclinical development of davunetide (NAP) as a peptide-drug candidate","volume":"32","author":"Gozes","year":"2011","journal-title":"Peptides"},{"key":"10.1016\/j.schres.2016.11.027_bb0190","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1023\/A:1025053115583","article-title":"P-glycoprotein attenuates brain uptake of substrates after nasal instillation","volume":"20","author":"Graff","year":"2003","journal-title":"Pharm. Res."},{"key":"10.1016\/j.schres.2016.11.027_bb0195","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.pharmthera.2012.03.003","article-title":"Intranasal drug delivery: an efficient and non-invasive route for systemic administration: focus on opioids","volume":"134","author":"Grassin-Delyle","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.schres.2016.11.027_bb0200","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.cct.2015.08.011","article-title":"Position on zinc delivery to olfactory nerves in intranasal insulin phase I-III clinical trials","volume":"45","author":"Hamidovic","year":"2015","journal-title":"Contemp. Clin. Trials."},{"key":"10.1016\/j.schres.2016.11.027_bb0205","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.ahj.2005.02.007","article-title":"Schizophrenia and increased risks of cardiovascular disease","volume":"150","author":"Hennekens","year":"2005","journal-title":"Am. Heart J."},{"key":"10.1016\/j.schres.2016.11.027_bb0210","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.euroneuro.2014.02.001","article-title":"Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial","volume":"24","author":"Hosseini","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2016.11.027_bb0215","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/0024-3205(95)02240-5","article-title":"Studies on the metabolism of haloperidol (HP): the role of CYP3A in the production of the neurotoxic pyridinium metabolite HPP+ found in rat brain following ip administration of HP","volume":"57","author":"Igarashi","year":"1995","journal-title":"Life Sci."},{"key":"10.1016\/j.schres.2016.11.027_bb0220","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1211\/0022357022539","article-title":"Is nose-to-brain transport of drugs in man a reality?","volume":"56","author":"Illum","year":"2004","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.schres.2016.11.027_bb0225","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/jps.20718","article-title":"Nanoparticulate systems for nasal delivery of drugs: a real improvement over simple systems?","volume":"96","author":"Illum","year":"2007","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.schres.2016.11.027_bb0230","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1124\/jpet.301.1.391","article-title":"Intranasal delivery of morphine","volume":"301","author":"Illum","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.schres.2016.11.027_bb0235","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/1061186021000001823","article-title":"Visualization of in vivo olfactory uptake and transfer using fluorescein dextran","volume":"10","author":"Jansson","year":"2002","journal-title":"J. Drug Target."},{"key":"10.1016\/j.schres.2016.11.027_bb0240","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1743-8454-1-2","article-title":"Evidence of connections between cerebrospinal fluid and nasal lymphatic vessels in humans, non-human primates and other mammalian species","volume":"1","author":"Johnston","year":"2004","journal-title":"Cerebrospinal Fluid Res."},{"key":"10.1016\/j.schres.2016.11.027_bb0245","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1177\/1060028015583893","article-title":"Alternate routes of administration of antidepressant and antipsychotic medications","volume":"49","author":"Kaminsky","year":"2015","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.schres.2016.11.027_bb0250","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1023\/A:1007583422634","article-title":"Enhancement of the systemic and CNS specific delivery of l-dopa by the nasal administration of its water soluble prodrugs","volume":"17","author":"Kao","year":"2000","journal-title":"Pharm. Res."},{"key":"10.1016\/j.schres.2016.11.027_bb0255","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1208\/s12248-014-9596-5","article-title":"Rapid delivery of diazepam from supersaturated solutions prepared using prodrug\/enzyme mixtures: toward intranasal treatment of seizure emergencies","volume":"16","author":"Kapoor","year":"2014","journal-title":"AAPS J."},{"key":"10.1016\/j.schres.2016.11.027_bb0260","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1021\/acs.molpharmaceut.5b00402","article-title":"Brain targeting of a water insoluble antipsychotic drug haloperidol via the intranasal route using PAMAM dendrimer","volume":"12","author":"Katare","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.schres.2016.11.027_bb0265","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2337\/diabetes.48.3.557","article-title":"Central nervous system effects of intranasally administered insulin during euglycemia in men","volume":"48","author":"Kern","year":"1999","journal-title":"Diabetes"},{"key":"10.1016\/j.schres.2016.11.027_bb0270","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jconrel.2014.06.053","article-title":"Quantitative analysis of drug delivery to the brain via nasal route","volume":"189","author":"Kozlovskaya","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.schres.2016.11.027_bb0275","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ijpharm.2008.03.029","article-title":"Intranasal nanoemulsion based brain targeting drug delivery system of risperidone","volume":"358","author":"Kumar","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.schres.2016.11.027_bb0280","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1080\/10611860802476504","article-title":"Mucoadhesive nanoemulsion-based intranasal drug delivery system of olanzapine for brain targeting","volume":"16","author":"Kumar","year":"2008","journal-title":"J. Drug Target."},{"key":"10.1016\/j.schres.2016.11.027_bb0285","doi-asserted-by":"crossref","first-page":"430","DOI":"10.2133\/dmpk.DMPK-10-RG-049","article-title":"Lack of a primary physicochemical determinant in the direct transport of drugs to the brain after nasal administration in rats: potential involvement of transporters in the pathway","volume":"25","author":"Lee","year":"2010","journal-title":"Drug Metab Pharmacokinet."},{"key":"10.1016\/j.schres.2016.11.027_bb0290","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.schres.2013.01.001","article-title":"Effects of adjunctive intranasal oxytocin on olfactory identification and clinical symptoms in schizophrenia: results from a randomized double blind placebo controlled pilot study","volume":"145","author":"Lee","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2016.11.027_bb0295","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.schres.2016.02.014","article-title":"Relationship of plasma oxytocin levels to baseline symptoms and symptom changes during three weeks of daily oxytocin administration in people with schizophrenia","volume":"172","author":"Lee","year":"2016","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2016.11.027_bb0300","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.biopsych.2015.05.003","article-title":"Intranasal oxytocin: myths and delusions","volume":"79","author":"Leng","year":"2016","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2016.11.027_bb0305","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/glia.20241","article-title":"Olfactory ensheathing cells and olfactory nerve fibroblasts maintain continuous open channels for regrowth of olfactory nerve fibres","volume":"52","author":"Li","year":"2005","journal-title":"Glia"},{"key":"10.1016\/j.schres.2016.11.027_bb0310","first-page":"20","article-title":"Managing anticholinergic side effects","volume":"6","author":"Lieberman","year":"2004","journal-title":"Prim Care Companion J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2016.11.027_bb0315","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejps.2005.06.003","article-title":"Transport of anti-allergic drugs across the passage cultured human nasal epithelial cell monolayer","volume":"26","author":"Lin","year":"2005","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.schres.2016.11.027_bb0320","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1007\/s11095-011-0641-0","article-title":"Nose-to-brain transport pathways of wheat germ agglutinin conjugated PEG-PLA nanoparticles","volume":"29","author":"Liu","year":"2012","journal-title":"Pharm. Res."},{"key":"10.1016\/j.schres.2016.11.027_bb0325","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.addr.2011.11.002","article-title":"Intranasal delivery of biologics to the central nervous system","volume":"64","author":"Lochhead","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.schres.2016.11.027_bb0330","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3389\/fnins.2013.00035","article-title":"Helping oxytocin deliver: considerations in the development of oxytocin-based therapeutics for brain disorders","volume":"7","author":"Macdonald","year":"2013","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.schres.2016.11.027_bb0335","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/0009-2797(72)90063-4","article-title":"Distribution of haloperidol and trifluperidol in brain and blood of rats","volume":"4","author":"Marcucci","year":"1972","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.schres.2016.11.027_bb0340","series-title":"Clinical Psychopharmacology: A Practical Approach","first-page":"70","author":"Marin","year":"2013"},{"key":"10.1016\/j.schres.2016.11.027_bb0345","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jps.21793","article-title":"Non-invasive systemic drug delivery: developability considerations for alternate routes of administration","volume":"99","author":"Mathias","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.schres.2016.11.027_bb0350","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/jps.2600760709","article-title":"Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity","volume":"76","author":"McMartin","year":"1987","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.schres.2016.11.027_bb0355","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.3109\/03639045.2015.1052081","article-title":"Nanoneurotherapeutics approach intended for direct nose to brain delivery","volume":"41","author":"Md","year":"2015","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.schres.2016.11.027_bb0360","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.peptides.2010.04.011","article-title":"NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse\u2014a microtubule-deficient model of schizophrenia","volume":"31","author":"Merenlender-Wagner","year":"2010","journal-title":"Peptides"},{"key":"10.1016\/j.schres.2016.11.027_bb0365","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/0192623307310946","article-title":"Drug nanoparticles: formulating poorly water-soluble compounds","volume":"36","author":"Merisko-Liversidge","year":"2008","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.schres.2016.11.027_bb0370","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0169-409X(97)00059-8","article-title":"Nasal mucociliary clearance as a factor in nasal drug delivery","volume":"29","author":"Merkus","year":"1998","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.schres.2016.11.027_bb0375","doi-asserted-by":"crossref","first-page":"E8","DOI":"10.1002\/jhm.691","article-title":"The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond?","volume":"5","author":"Meyer-Massetti","year":"2010","journal-title":"J. Hosp. Med."},{"key":"10.1016\/j.schres.2016.11.027_bb0380","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1592\/phco.28.7.875","article-title":"Comparison of intranasal administration of haloperidol with intravenous and intramuscular administration: a pilot pharmacokinetic study","volume":"28","author":"Miller","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.schres.2016.11.027_bb0385","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/10611860903055470","article-title":"Effect of physicochemical properties on intranasal nanoparticle transit into murine olfactory epithelium","volume":"17","author":"Mistry","year":"2009","journal-title":"J. Drug Target."},{"key":"10.1016\/j.schres.2016.11.027_bb0390","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ijpharm.2009.06.019","article-title":"Nanoparticles for direct nose-to-brain delivery of drugs","volume":"379","author":"Mistry","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.schres.2016.11.027_bb0395","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s40263-012-0022-1","article-title":"Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia: an 8-week, randomized, double-blind, placebo-controlled study","volume":"27","author":"Modabbernia","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.schres.2016.11.027_bb0400","doi-asserted-by":"crossref","first-page":"260","DOI":"10.5498\/wjp.v5.i3.260","article-title":"Role of presynaptic phosphoprotein synapsin II in schizophrenia","volume":"5","author":"Molinaro","year":"2015","journal-title":"World J. Psychiatry"},{"key":"10.1016\/j.schres.2016.11.027_bb0405","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1176\/ajp.139.12.1571","article-title":"Efficacy and side effects of haloperidol in psychotic patients: oral versus intravenous administration","volume":"139","author":"Moller","year":"1982","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2016.11.027_bb0410","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.2337\/diab.32.11.1040","article-title":"Insulin administered intranasally as an insulin-bile salt aerosol. Effectiveness and reproducibility in normal and diabetic subjects","volume":"32","author":"Moses","year":"1983","journal-title":"Diabetes"},{"key":"10.1016\/j.schres.2016.11.027_bb0415","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.amjopharm.2010.03.003","article-title":"Alternative formulations, delivery methods, and administration options for psychotropic medications in elderly patients with behavioral and psychological symptoms of dementia","volume":"8","author":"Muramatsu","year":"2010","journal-title":"Am. J. Geriatr. Pharmacother."},{"key":"10.1016\/j.schres.2016.11.027_bb0420","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.pnpbp.2007.01.023","article-title":"Effects of haloperidol and its pyridinium metabolite on plasma membrane permeability and fluidity in the rat brain","volume":"31","author":"Murata","year":"2007","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2016.11.027_bb0425","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1527-3458.2001.tb00199.x","article-title":"Pharmacology of the atypical antipsychotic remoxipride, a dopamine D2 receptor antagonist","volume":"7","author":"Nadal","year":"2001","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.schres.2016.11.027_bb0430","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1742-2094-10-43","article-title":"Neuroinflammation and psychiatric illness","volume":"10","author":"Najjar","year":"2013","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.schres.2016.11.027_bb0435","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1124\/jpet.107.132381","article-title":"Delivery of galanin-like peptide to the brain: targeting with intranasal delivery and cyclodextrins","volume":"325","author":"Nonaka","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.schres.2016.11.027_bb0440","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1007\/s40265-013-0130-3","article-title":"Alternative delivery systems for agents to treat acute agitation: progress to date","volume":"73","author":"Nordstrom","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.schres.2016.11.027_bb0445","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0024-3205(97)00149-5","article-title":"The first attempt at radioisotopic evaluation of the integrity of the nose-brain barrier","volume":"60","author":"Okuyama","year":"1997","journal-title":"Life Sci."},{"key":"10.1016\/j.schres.2016.11.027_bb0450","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00406-015-0634-9","article-title":"Efficacy and safety of oxytocin augmentation therapy for schizophrenia: an updated systematic review and meta-analysis of randomized, placebo-controlled trials","volume":"266","author":"Oya","year":"2016","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.schres.2016.11.027_bb0455","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/pnp.267","article-title":"Is autoimmunity involved in the aetiology of schizophrenia?","volume":"17","author":"Pandarakalam","year":"2013","journal-title":"Prog. Neurol. Psychiatry"},{"key":"10.1016\/j.schres.2016.11.027_bb0460","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","article-title":"The blood\u2013brain barrier: bottleneck in brain drug development","volume":"2","author":"Pardridge","year":"2005","journal-title":"NeuroRx"},{"key":"10.1016\/j.schres.2016.11.027_bb0465","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3109\/10717544.2014.914602","article-title":"Paliperidone microemulsion for nose-to-brain targeted drug delivery system: pharmacodynamic and pharmacokinetic evaluation","volume":"23","author":"Patel","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.schres.2016.11.027_bb0470","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3109\/1061186X.2010.523787","article-title":"Brain targeting of risperidone-loaded solid lipid nanoparticles by intranasal route","volume":"19","author":"Patel","year":"2011","journal-title":"J. Drug Target."},{"key":"10.1016\/j.schres.2016.11.027_bb0475","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.schres.2011.07.027","article-title":"Intranasal oxytocin reduces psychotic symptoms and improves theory of mind and social perception in schizophrenia","volume":"132","author":"Pedersen","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2016.11.027_bb0480","first-page":"1373","article-title":"Increased brain radioactivity by intranasal P-labeled siRNA dendriplexes within in situ-forming mucoadhesive gels","volume":"7","author":"Perez","year":"2012","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.schres.2016.11.027_bb0485","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejpb.2014.02.007","article-title":"Haloperidol-loaded intranasally administered lectin functionalized poly(ethylene glycol)-block-poly(d,l)-lactic-co-glycolic acid (PEG-PLGA) nanoparticles for the treatment of schizophrenia","volume":"87","author":"Piazza","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.schres.2016.11.027_bb0490","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1115\/1.4029907","article-title":"A novel intranasal spray device for the administration of nanoparticles to reodents","volume":"9","author":"Piazza","year":"2015","journal-title":"J. Med. Devices"},{"key":"10.1016\/j.schres.2016.11.027_bb0495","doi-asserted-by":"crossref","first-page":"288","DOI":"10.18433\/J3NC79","article-title":"Intranasal drug delivery: how, why and what for?","volume":"12","author":"Pires","year":"2009","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.schres.2016.11.027_bb9005","article-title":"Revisiting loxapine: a systematic review","volume":"14:15","author":"Popovic","year":"2015","journal-title":"Ann. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2016.11.027_bb0500","author":"PubChem Substance and Compound Database"},{"key":"10.1016\/j.schres.2016.11.027_bb0505","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ijpharm.2014.04.015","article-title":"Development, characterization and application of in situ gel systems for intranasal delivery of tacrine","volume":"468","author":"Qian","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.schres.2016.11.027_bb0510","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2015.93","article-title":"Low-dose oxytocin delivered intranasally with breath powered device affects social-cognitive behavior: a randomized four-way crossover trial with nasal cavity dimension assessment","volume":"5","author":"Quintana","year":"2015","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.schres.2016.11.027_bb0515","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3109\/03602539308993975","article-title":"Drug metabolism in the nasal cavity: relevance to toxicology","volume":"25","author":"Reed","year":"1993","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.schres.2016.11.027_bb0520","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1212\/01.WNL.0000265401.62434.36","article-title":"Intranasal insulin improves cognition and modulates beta-amyloid in early AD","volume":"70","author":"Reger","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.schres.2016.11.027_bb0525","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.pharmthera.2009.10.010","article-title":"Metabolic side effects of antipsychotic drug treatment\u2014pharmacological mechanisms","volume":"125","author":"Reynolds","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.schres.2016.11.027_bb0530","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1001\/archpsyc.64.10.1123","article-title":"A systematic review of mortality in schizophrenia \u2014 is the differential mortality gap worsening over time?","volume":"64","author":"Saha","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2016.11.027_bb0535","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3109\/08982104.2012.700460","article-title":"Brain delivery of olanzapine by intranasal administration of transfersomal vesicles","volume":"22","author":"Salama","year":"2012","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.schres.2016.11.027_bb0540","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.colsurfb.2012.05.010","article-title":"Phospholipid based colloidal poloxamer-nanocubic vesicles for brain targeting via the nasal route","volume":"100","author":"Salama","year":"2012","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.schres.2016.11.027_bb0545","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s40263-013-0054-1","article-title":"Antipsychotic-induced metabolic and cardiovascular side effects in schizophrenia: a novel mechanistic hypothesis","volume":"27","author":"Scigliano","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.schres.2016.11.027_bb0550","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1016\/j.actbio.2011.07.025","article-title":"Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: in vitro and in vivo studies","volume":"7","author":"Seju","year":"2011","journal-title":"Acta Biomater."},{"key":"10.1016\/j.schres.2016.11.027_bb0555","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s00213-003-1506-y","article-title":"Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia","volume":"169","author":"Sharma","year":"2003","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.schres.2016.11.027_bb0560","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1177\/0269881114541013","article-title":"Re-examining the role of benzodiazepines in the treatment of schizophrenia: a systematic review","volume":"29","author":"Sim","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.schres.2016.11.027_bb0565","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.colsurfb.2008.07.004","article-title":"Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size","volume":"66","author":"Sonavane","year":"2008","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.schres.2016.11.027_bb0570","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1124\/dmd.111.040782","article-title":"Systemic and direct nose-to-brain transport pharmacokinetic model for remoxipride after intravenous and intranasal administration","volume":"39","author":"Stevens","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.schres.2016.11.027_bb0575","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/cbdd.12268","article-title":"Novel central nervous system drug delivery systems","volume":"83","author":"Stockwell","year":"2014","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.schres.2016.11.027_bb0580","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1038\/srep03440","article-title":"Elevated cerebrospinal fluid and blood concentrations of oxytocin following its intranasal administration in humans","volume":"3","author":"Striepens","year":"2013","journal-title":"Sci. Rep."},{"key":"10.1016\/j.schres.2016.11.027_bb0585","doi-asserted-by":"crossref","first-page":"679","DOI":"10.2217\/17435889.3.5.679","article-title":"Dendrimers for enhanced drug solubilization","volume":"3","author":"Svenson","year":"2008","journal-title":"Nanomedicine (Lond.)"},{"key":"10.1016\/j.schres.2016.11.027_bb0590","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.peptides.2013.02.004","article-title":"Preclinical pharmacokinetic and toxicological evaluation of MIF-1 peptidomimetic, PAOPA: examining the pharmacology of a selective dopamine D2 receptor allosteric modulator for the treatment of schizophrenia","volume":"42","author":"Tan","year":"2013","journal-title":"Peptides"},{"key":"10.1016\/j.schres.2016.11.027_bb0595","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1023\/A:1011922819926","article-title":"Stealth PLA-PEG nanoparticles as protein carriers for nasal administration","volume":"15","author":"Tobio","year":"1998","journal-title":"Pharm. Res."},{"key":"10.1016\/j.schres.2016.11.027_bb0600","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1021\/bc034164r","article-title":"Nanogels for oligonucleotide delivery to the brain","volume":"15","author":"Vinogradov","year":"2004","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.schres.2016.11.027_bb0605","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1017\/S1461145704004390","article-title":"The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein","volume":"7","author":"Wang","year":"2004","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2016.11.027_bb0610","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ijpharm.2006.02.055","article-title":"Evaluation of brain-targeting for the nasal delivery of estradiol by the microdialysis method","volume":"317","author":"Wang","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.schres.2016.11.027_bb0615","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/cne.11045","article-title":"Response of olfactory ensheathing cells to the degeneration and regeneration of the peripheral olfactory system and the involvement of the neuregulins","volume":"470","author":"Williams","year":"2004","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.schres.2016.11.027_bb0620","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1007\/s11095-014-1312-8","article-title":"Pharmacokinetic comparison between the long-term anesthetized, short-term anesthetized and conscious rat models in nasal drug delivery","volume":"31","author":"Wong","year":"2014","journal-title":"Pharm. Res."},{"key":"10.1016\/j.schres.2016.11.027_bb0625","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1007\/s11095-013-1080-x","article-title":"Brain disposition and catalepsy after intranasal delivery of loxapine: role of metabolism in PK\/PD of intranasal CNS drugs","volume":"30","author":"Wong","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.schres.2016.11.027_bb0630","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1177\/0004867412453625","article-title":"Use of first- and second-generation antipsychotic medications in older patients with schizophrenia in Asia (2001\u20132009)","volume":"46","author":"Xiang","year":"2012","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.schres.2016.11.027_bb0635","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.apsb.2014.10.005","article-title":"Solid lipid nanoparticles for nose to brain delivery of haloperidol: in vitro drug release and pharmacokinetics evaluation","volume":"4","author":"Yasir","year":"2014","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.schres.2016.11.027_bb0640","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2217\/14796708.3.1.1","article-title":"The nose may help the brain: intranasal drug delivery for treating neurological diseases","volume":"3","author":"Ying","year":"2008","journal-title":"Future Neurol."},{"key":"10.1016\/j.schres.2016.11.027_bb0645","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1080\/10611860600721051","article-title":"The brain targeting efficiency following nasally applied MPEG-PLA nanoparticles in rats","volume":"14","author":"Zhang","year":"2006","journal-title":"J. Drug Target."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996416305205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996416305205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,15]],"date-time":"2019-09-15T22:49:22Z","timestamp":1568587762000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996416305205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":130,"alternative-id":["S0920996416305205"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2016.11.027","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intranasal delivery of antipsychotic drugs","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2016.11.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}